Your browser doesn't support javascript.
Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski, Maciej; de Jager, Wilco; Schiuma, Marco; Covizzi, Alice; Lai, Alessia; Gabrieli, Arianna; Corbellino, Mario; Bergna, Annalisa; Ventura, Carla Della; Galli, Massimo; Riva, Agostino; Antinori, Spinello.
  • Tarkowski M; Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy.
  • de Jager W; Luminex B.V., Hertogenbosch, Netherlands.
  • Schiuma M; Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy.
  • Covizzi A; Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy.
  • Lai A; Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy.
  • Gabrieli A; Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy.
  • Corbellino M; Division of Infectious Diseases, Aziende Socio Sanitarie Territoriali (ASST) Fatebenefratelli Sacco Hospital, Milan, Italy.
  • Bergna A; Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy.
  • Ventura CD; Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy.
  • Galli M; Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy.
  • Riva A; Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy.
  • Antinori S; Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy.
Front Immunol ; 12: 793191, 2021.
Article Dans Anglais | MEDLINE | ID: covidwho-1608200
ABSTRACT

Purpose:

To compare SARS-CoV-2 antigen-specific antibody production and plasma neutralizing capacity against B.1 wild-type-like strain, and Gamma/P.1 and Delta/B.1.617.2 variants-of-concern, in subjects with different Covid-19 disease and vaccination histories.

Methods:

Adult subjects were 1) Unvaccinated/hospitalized for Covid-19; 2) Covid-19-recovered followed by one BNT162b2 vaccine dose; and 3) Covid-19-naïve/2-dose BNT162b2 vaccinated. Multiplex Luminex® immunoassays measured IgG, IgA, and IgM plasma levels against SARS-CoV-2 receptor-binding domain (RBD), spike-1 (S), and nucleocapsid proteins. Neutralizing activity was determined in Vero E6 cytopathic assays.

Results:

Maximum anti-RBD IgG levels were similar in Covid-19­recovered individuals 8‒10 days after single-dose vaccination and in Covid-19-naïve subjects 7 days after 2nd vaccine dosing; both groups had ≈2­fold higher anti-RBD IgG levels than Unvaccinated/Covid-19 subjects tracked through 2 weeks post-symptom onset. Anti-S IgG expression patterns were similar to RBD within each group, but with lower signal strengths. Viral antigen-specific IgA and IgM levels were more variable than IgG patterns. Anti-nucleocapsid immunoglobulins were not detected in Covid-19-naïve subjects. Neutralizing activity against the B.1 strain, and Gamma/P.1 and Delta/B.1.617.2 variants, was highest in Covid­19-recovered/single-dose vaccinated subjects; although neutralization against the Delta variant in this group was only 26% compared to B.1 neutralization, absolute anti-Delta titers suggested maintained protection. Neutralizing titers against the Gamma and Delta variants were 33‒77% and 26‒67%, respectively, versus neutralization against the B.1 strain (100%) in the three groups.

Conclusion:

These findings support SARS-CoV-2 mRNA vaccine usefulness regardless of Covid-19 history, and confirm remarkable protection provided by a single vaccine dose in people who have recovered from Covid-19.
Sujets)
Mots clés

Texte intégral: Disponible Collection: Bases de données internationales Base de données: MEDLINE Sujet Principal: Isotypes des immunoglobulines / Anticorps neutralisants / SARS-CoV-2 / COVID-19 / Vaccin BNT162 / Anticorps antiviraux Type d'étude: Études expérimentales / Étude pronostique / Essai contrôlé randomisé Les sujets: Vaccins / Variantes Limites du sujet: Adulte / Adulte très âgé / Animaux / Femelle / Humains / Mâle / Adulte d'âge moyen langue: Anglais Revue: Front Immunol Année: 2021 Type de document: Article Pays d'affiliation: Fimmu.2021.793191

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS


Texte intégral: Disponible Collection: Bases de données internationales Base de données: MEDLINE Sujet Principal: Isotypes des immunoglobulines / Anticorps neutralisants / SARS-CoV-2 / COVID-19 / Vaccin BNT162 / Anticorps antiviraux Type d'étude: Études expérimentales / Étude pronostique / Essai contrôlé randomisé Les sujets: Vaccins / Variantes Limites du sujet: Adulte / Adulte très âgé / Animaux / Femelle / Humains / Mâle / Adulte d'âge moyen langue: Anglais Revue: Front Immunol Année: 2021 Type de document: Article Pays d'affiliation: Fimmu.2021.793191